ReviewEye (London, England)2025
Coats-like vasculopathy in patients with an inherited retinal disease: a case series and literature review.
Review in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coats-like exudative vasculopathy in a patient with Bardet-Biedl syndrome.American journal of ophthalmology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine clinical characteristics, genetic associations, and visual outcomes of Coats-like vasculopathy (CLV) in patients with inherited retinal disease (IRD).
methodsA literature review of studies published through December 30, 2023, and a cohort analysis of cases from Hadassah Medical Center were conducted. Data from 47 studies (163 patients, 277 eyes) and 10 institutional cases (17 eyes) were analysed using descriptive statistics.
resultsTwo novel CLV-associated genes, LRP5 and KIZ, were identified in our cohort. Literature findings showed that 69.9% of cases had bilateral asymmetric CLV, with 38.7% of patients being legally blind at their final assessment. The mean interval between IRD onset and CLV diagnosis was 10.38 ± 10.23 years. While baseline best-corrected visual acuity (BCVA) showed no significant difference between unilateral CLV-affected vs. non-CLV-affected eyes (51.19 vs. 72 ETDRS letters, respectively; p = 0.051), BCVA was significantly different at CLV onset (29.19 vs. 69.12 ETDRS letters, respectively; p < 0.001) and at the final visit (19.93 vs. 63.55 ETDRS letters, respectively; p < 0.001). Visual outcomes were similar across treatment modalities (laser, cryotherapy ± laser).
conclusionsCLV in IRD patients demonstrates clinical and genetic heterogeneity, with significant visual impairment regardless of treatment. The discovery of LRP5 and KIZ expands the genetic landscape of CLV. The profound and progressive vision loss in CLV-affected eyes underscores the need for early detection and tailored management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.